Loading
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Previous close
$18.90
+$0.30 · +1.61%
After-hours
$19.15
+$0.25 · +1.32%
Oct 14, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Day range
Current $18.90
52-week range
Current $18.90
Regular session · ET · Market data may be delayed.
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Day range
Current $18.90
52-week range
Current $18.90
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 570K USD | 501K USD | 424K USD | 477K USD | 931K USD |
| Cost of goods sold | 23K USD | — | — | — | — |
| Gross profit | 547K USD | 501K USD | 424K USD | 477K USD | 931K USD |
| Research and development | 19.24M USD | 30.95M USD | 16.31M USD | 18.39M USD | 19.54M USD |
| Selling, general, and administrative | 11.08M USD | 13.19M USD | 13.38M USD | 16.39M USD | 20.3M USD |
| Operating expenses | 30.3M USD | 44.14M USD | 29.68M USD | 34.77M USD | 39.84M USD |
| Interest expense | — | — | — | — | 5.61M USD |
| Depreciation and amortization | 23K USD | 4K USD | — | 72K USD | 109K USD |
| Operating income | −29.75M USD | −43.64M USD | −29.26M USD | −34.3M USD | −38.91M USD |
| Net income | −26.48M USD | −39.83M USD | −28.45M USD | −23.21M USD | −73.33M USD |
Company facts updated Oct 15, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.75
69.58% downside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 24, 2026 | $0.402Irregular | Jul 22, 2026 | — |
Ex-dividend Jul 24, 2026
$0.402
Irregular
Record Jul 22, 2026
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
U.S. Micro Cap Portfolio ETFDFMCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
